| KUMAMOTO UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120058491 | METHOD FOR INDUCTION OF DIFFERENTIATION OF ES CELL - It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M. | 03-08-2012 |
| 20110229487 | THERAPEUTIC AGENT COMPRISING ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB-1 AS ACTIVE INGREDIENT - Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect. | 09-22-2011 |
| 20110044995 | ANTI-HIV MONOCLONAL ANTIBODY - The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies:
| 02-24-2011 |
| 20100219068 | Harmful Gas Treatment Apparatus and Water Treatment Apparatus - A harmful gas treatment apparatus and a water treatment apparatus uses an electrochemical device provided with a solid electrolyte membrane having ion conductivity. A first electrochemical device provided with an anode on one surface of a hydrogen ion conductive electrolyte membrane and a cathode on the other surface thereof is combined with a second electrochemical device provided with an anode on one surface of a hydroxyl ion conductive electrolyte membrane and a cathode on the other surface thereof. Both cathodes are disposed so as to face each other within an electrochemical reaction tank. Each of the cathodes is provided with TiO | 09-02-2010 |
| 20090239806 | GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME - It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):
| 09-24-2009 |
| 20090215716 | NITROGUANOSINE-3' 5'-CYCLIC MONOPHOSPHATE COMPOUND AND PROTEIN KINASE G ACTIVATING AGENT - An object of the present invention is to provide a novel compound that is an agonist of guanosine-3′,5′-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3′,5′-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3′,5′-cyclic monophosphate compound as an active ingredient. | 08-27-2009 |
| 20090111095 | NOVEL DIAGNOSTIC KIT FOR MALIGNANT MELANOMA - The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3. | 04-30-2009 |
| 20090022692 | THERAPEUTIC AGENT FOR HEART DISEASE USING MAP KINASE TNNI3K - An object to be achieved by the present invention is to provide a therapeutic means for heart disease such as myocardial ischemia or myocardial infarction. The present invention provides a therapeutic agent for heart disease which comprises a myocardial progenitor cell expressing MAP kinase TNNI3K at a high level as an active ingredient. | 01-22-2009 |
